Failure to induce clinical remission at end of study · Participants with active Crohn's disease despite current treatment with infliximab
Three infusions of natalizumab (300 mg) and two infusions of… showed no clear difference in failure to induce clinical remission at week 10 compared with placebo and two infusions of infliximab (moderate certainty).
1 finding from 1 review
Failure to induce clinical response at end of study · Participants with active Crohn's disease despite current treatment with infliximab
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events up to week 10 · Participants with active Crohn's disease despite current treatment with infliximab
Three infusions of natalizumab (300 mg) and two infusions of… showed no clear difference in adverse events up to week 10 compared with placebo and two infusions of infliximab (moderate certainty).
1 finding from 1 review
Withdrawals due to adverse outcomes · Participants with active Crohn's disease despite current treatment with infliximab
Three infusions of natalizumab (300 mg) and two infusions of… showed no clear difference in withdrawal due to adverse events up to week 10 compared with placebo and two infusions of infliximab (low certainty).
1 finding from 1 review
Serious adverse events up to week 10 · Participants with active Crohn's disease despite current treatment with infliximab
Three infusions of natalizumab (300 mg) and two infusions of… showed no clear difference in serious adverse events up to week 10 compared with placebo and two infusions of infliximab (low certainty).
1 finding from 1 review
Failure to induce remission at 10 weeks · Patients with active Crohn's disease
Three infusions of natalizumab (300 mg) showed no clear difference in failure to induce remission at 10 weeks compared with placebo (high certainty).
2 findings from 1 review
Failure to induce clinical response at end of study · Patients with active Crohn's disease
Three infusions of natalizumab (300 mg) showed no clear difference in failure to induce clinical response at 10 weeks compared with placebo (high certainty).
2 findings from 1 review
Adverse events up to week 12 · Patients with active Crohn's disease
Three infusions of natalizumab (300 mg) showed no clear difference in adverse events up to week 12 compared with placebo (high certainty).
1 finding from 1 review
Withdrawals due to adverse events · Patients with active Crohn's disease
Three infusions of natalizumab (300 mg) showed no clear difference in withdrawal due to adverse event up to week 12 compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse events up to week 12 · Patients with active Crohn's disease
Three infusions of natalizumab (300 mg) showed no clear difference in serious adverse events up to week 12 compared with placebo (low certainty).
1 finding from 1 review